Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to Intra-Cellular Therapies First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Intra-Cellular Therapies Inc. (ITCI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 1,700,000 | $92,055,000 | 3.78% | |
| 2. | Suvretta Capital Management Aaron Cowen | 1,198,971 | $64,924,280 | +16% | 2.74% |
| 3. | Holocene Advisors Brandon Haley | 1,116,264 | $60,445,696 | -36% | 0.29% |
| 4. | Deerfield Management James E. Flynn | 734,000 | $39,746,100 | 0.88% | |
| 5. | Citadel Investment Group Ken Griffin | 613,756 | $33,234,888 | -8% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.60 | 49,500 | Director | 4,743,770 | 2020-09-14 | Filing | |
| $28.08 | 21,000 | Director | 4,694,270 | 2020-09-11 | Filing | |
| $11.00 | 6,240 | Large Shareholder, Director | 4,673,270 | 2019-09-10 | Filing | |
| $10.58 | 320,095 | Large Shareholder, Director | 4,667,030 | 2019-09-10 | Filing | |
| $9.59 | 155,116 | Large Shareholder, Director | 4,346,935 | 2019-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $63.00 | 10,000 | Director | 9,345 | 2023-04-17 | Filing | |
| $54.01 | 10,183 | Officer | 45,339 | 2023-03-28 | Filing | |
| $54.86 | 5,421 | Officer | 55,522 | 2023-03-28 | Filing | |
| $44.29 | 346 | Officer | 23,104 | 2023-03-13 | Filing | |
| $45.08 | 6,998 | Officer | 23,450 | 2023-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 11,940,141 | $646,558,655 | 0.05% | |
| 2. | 8,443,157 | $457,196,951 | 0.01% | |
| 3. | 7,268,832 | $393,607,252 | 0.01% | |
| 4. | 5,024,783 | $272,092,000 | 0.05% | |
| 5. | 4,479,576 | $242,569,040 | 1.51% |
News See All
12 Most Promising Healthcare Stocks According to Analysts
In this article, we will take a look at the 12 most promising healthcare stocks according to analysts.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Intra-Cellular Therapies Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
5 High Growth Healthcare Stocks to Buy
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is one of the high growth healthcare companies that is working on treatments for neuropsychiatric and neurologic disorders.
Is Intra-Cellular Therapies (ITCI) a Worthy Investment Option?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here.
Should You Retain Your Holdings in Intra-Cellular Therapies (ITCI)?
Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Ultra Strategy” third-quarter 2022 investor letter. A copy of the same can be downloaded here.
Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy?
ClearBridge Investments, an investment management company, published its “ClearBridge Small Cap Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Wasatch Global's Strongest Q1 Contributor: Intra-Cellular Therapies (ITCI)
Wasatch Global Investors, an investment management firm, published its “Wasatch Ultra Growth Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Is it a Great Choice to Invest in Intra-Cellular Therapies, Inc. (ITCI)?
ClearBridge Investments, an investment management firm, published its “Small Cap Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Should You Consider Investing in Intra-Cellular Therapies (ITCI)?
Wasatch Global Investors, an investment management firm, published its “Wasatch Small Cap Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
